BCG vaccine can help elderly fight against Covid-19, says ICMR study

The Bacille Calmette-Guerin or BCG vaccine, originally made against tuberculosis, may help in the management of Covid-19, especially in the elderly, says a study by the ICMR

Coronavirus, vaccine, covid
IANS New Delhi
2 min read Last Updated : Oct 30 2020 | 6:07 PM IST

The Bacille Calmette-Guerin or BCG vaccine, originally made against tuberculosis, may help in the management of Covid-19, especially in the elderly, says a study by the Indian Council of Medical Research (ICMR).

The BCG vaccination is known to induce innate immune memory, which confers protection against several infections, the study uploaded as preprint at medRxiv, reported.

"We investigated the impact of BCG vaccination on the frequencies of T cell, B cell, monocyte and dendritic cell subsets," the study researchers from ICMR wrote.

"We also investigated total antibody levels in a group of healthy elderly individuals (age 60-80 years) at one month post vaccination as part of our clinical study to examine the effect of BCG on Covid-19," they added.

The results showed that BCG vaccination induces enhanced innate and adaptive immunity in elderly individuals which may prove beneficial against the coronavirus.

"Finally, BCG vaccination resulted in elevated levels of all antibody isotypes," the researchers wrote.

"BCG vaccination was associated with enhanced innate and adaptive memory cell subsets, as well as total antibody levels in elderly individuals," they concluded.

Earlier in October, as part of a large-scale global trial, scientists in Britain launched a study to test if the widely-used BCG vaccine could help protect people against Covid-19.

A study published in the journal 'Cell Reports Medicine', also revealed that the BCG vaccine has a general stimulating effect on the immune system and is, therefore, effective against Covid-19.

--IANS

bu/bg

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusICMR

First Published: Oct 30 2020 | 6:06 PM IST

Next Story